3,470
Views
44
CrossRef citations to date
0
Altmetric
Review

Chikungunya vaccines in development

, , , &
Pages 716-731 | Received 15 Jul 2015, Accepted 23 Sep 2015, Published online: 05 May 2016
 

ABSTRACT

Chikungunya virus has become a global health threat, spreading to the industrial world of Europe and the Americas; no treatment or prophylactic vaccine is available. Since the late 1960s much effort has been put into the development of a vaccine, and several heterogeneous strategies have already been explored. Only two candidates have recently qualified to enter clinical phase II trials, a chikungunya virus-like particle-based vaccine and a recombinant live attenuated measles virus-vectored vaccine.

This review focuses on the current status of vaccine development against chikungunya virus in humans and discusses the diversity of immunization strategies, results of recent human trials and promising vaccine candidates.

Abbreviations

CHIK=

Chikungunya

CHIKV=

Chikungunya Virus

DENV=

Dengue Virus

ECSA=

East/Central/Southern African subtype

ELISA=

Enzyme-linked Immunosorbent-assay

GMT=

Geometric Mean Titers

GP=

Glycoprotein

IgG=

Immunoglobulin G

IgM=

Immunoglobulin M

IFN(s)=

Interferon(s)

IOL=

Indian Ocean Lineage

IRES=

Internal Ribosome Entry Site

mAbs=

Monoclonal Antibodies

MTX=

Methotrexat

MV=

Measles Virus

NHP=

Non-Human Primate

nsP=

Non Structural Proteins

PRNT=

Plaque Reduction Neutralization Tests

RT-PCR=

Reverse-Transcriptase Polymerase Chain Reaction

(e)VLP=

(enveloped) Virus-Like Particles

VRC=

Vaccine Research Center

Disclosure of potential conflicts of interest

MS was an investigator of the MV-CHIK trial (PMID: 25739878). BJ served as a regulatory advisor to Themis GmbH. NB, PPW and CS declare no competing interests.

Acknowledgment

We would like to thank Stacy Dahl, M.A., B.A. (professional lector), for linguistic editing of the manuscript.